These therapies have shown remarkable success in patients with relapsed or treatment-resistant B cell cancers, leading to high complete remission rates in cases unresponsive to conventional treatments.443,444 The success of CAR-T cell therapy targeting CD19 has spurred the exploration of CAR-T therapies aimed at other antigens and various cancer types. The gene discussed is CD19; the disease is cancer.